openPR Logo
Press release

Investigation announced for Long-Term Investors in NASDAQ: BIIB shares over potential Wrongdoing at Biogen Inc.

02-23-2021 08:23 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

An investigation on behalf of current long term investors in Biogen Inc. (NASDAQ: BIIB) shares.

An investigation on behalf of current long term investors in Biogen Inc. (NASDAQ: BIIB) shares.

An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Biogen Inc..

Investors who are current long term investors in Biogen Inc. (NASDAQ: BIIB) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm for current long term investors in NASDAQ: BIIB stocks follows a lawsuit filed against Biogen Inc. over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: BIIB stocks, concerns whether certain Biogen Inc. directors are liable in connection with the allegations made in that lawsuit.

According to that complaint filed in the U.S. District Court for the Central District of California the plaintiff alleges that the defendants made false and/or misleading statements and/or failed to disclose that the larger dataset did not provide necessary data regarding aducanumab’s effectiveness, that the EMERGE study did not and would not provide necessary data regarding aducanumab’s effectiveness, that the PRIME study did not and would not provide necessary data regarding aducanumab’s effectiveness, that the data provided by the Company to the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee did not support finding efficacy of aducanumab, and that as a result, defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Those who purchased shares of Biogen Inc. (NASDAQ: BIIB) have certain options and should contact the Shareholders Foundation.

Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Investigation announced for Long-Term Investors in NASDAQ: BIIB shares over potential Wrongdoing at Biogen Inc. here

News-ID: 2247515 • Views: 340

More Releases from Shareholders Foundation

Investigation for Investors in NASDAQ: HCDI shares over possible Wrongdoing at H …
An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Harbor Custom Development, Inc. Investors who purchased shares of Harbor Custom Development, Inc. (NASDAQ: HCDI) and currently hold any of those NASDAQ: HCDI shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain Harbor Custom Development, Inc. directors breached
Lawsuit for Investors in Infinity Q Diversified Alpha Fund Investor Class (NASDA …
An investor, who purchased shares of Investors in Infinity Q Diversified Alpha Fund Investor Class (NASDAQ: IQDAX) and Infinity Q Diversified Alpha Fund Institutional Class (NASDAQ: IQDNX), filed a lawsuit over alleged violations of Securities Laws in connection with certain allegedly false and misleading statements made between December 31, 2018 through February 22, 2021. If you purchased a significant amount of shares of Investors in Infinity Q Diversified Alpha Fund
Investigation announced for Investors in shares of AquaBounty Technologies, Inc. …
An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at AquaBounty Technologies, Inc. Investors who purchased shares of AquaBounty Technologies, Inc. (NASDAQ: AQB) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain AquaBounty Technologies, Inc. directors breached their fiduciary duties and caused damage to the company and its shareholders. Maynard,
Lawsuit filed for Investors in shares of Velodyne Lidar, Inc. (NASDAQ: VLDR)
An investor, who purchased shares of Velodyne Lidar, Inc. (NASDAQ: VLDR), filed a lawsuit over alleged violations of Federal Securities Laws by Velodyne Lidar, Inc. in connection with certain allegedly false and misleading statements. Investors who purchased shares of Velodyne Lidar, Inc. (NASDAQ: VLDR) have certain options and for certain investors are short and strict deadlines running. Deadline: May 3, 2021. NASDAQ: VLDR investors should contact the Shareholders Foundation at

All 5 Releases


More Releases for Biogen

Europe Anaerobic Digestion Market Analysis Focusing on Top Key Players Biogen, C …
Market Study Report adds Europe Anaerobic Digestion market report that gives meticulous investigation of current scenario of the market size, share, demand, growth, trends, companies active in the industry and forecasts for the coming years. The Netherlands in 2016, accounted for over 4% annual capacity share across the Europe anaerobic digestion market. Cost competitive deployment of AD systems when compared to landfill and incineration based plants will appreciably drive the industry
Global Multiple Sclerosis (MS) Market 2018 Key Players: Bayer Healthcare, Merck …
Multiple Sclerosis (MS) Market: WiseGuyReports.com adds “Multiple Sclerosis (MS) Market 2018 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting 2027” reports tits database. Executive Summary DelveInsight’s Multiple Sclerosis (MS) - Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical &forecasted epidemiology as well as the market trends of Multiple Sclerosis (MS) in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan. The Report
Europe anaerobic digestion Market Detail Analysis focusing on Key Players BTS Bi …
The Europe anaerobic digestion market is projected to witness a commendable growth rate over the approaching years, on account of stringent government regulations to treat residues and waste with minimal ecological impact and burgeoning initiatives to uphold energy security. Apart from the factors mentioned above, other factors propelling the market include high operational performance, low emission rate, and cost-effectiveness of anaerobic digestion over other energy sources. Moreover, swift urbanization coupled
Recombinant Factor VIII Market Is Booming Worldwide | Pfizer, Biogen, Octapharma
A new independent 123 page research with title 'Global Recombinant Factor VIII Market Report 2018' guarantees you will remain better informed than your competition. The study covers geographic analysis that includes regions like North America, Europe, Asia, South America, Other Country and important players/vendors such as Shire (Baxter), Bayer, CSL etc. With n-number of tables and figures examining the Global Recombinant Factor VIII Market, the research gives you a visual,
Global Bleeding Disorders Treatment Market 2018 - Shire Plc, Bayer, Biogen
Apex Market Reports, recently published a detailed market research study focused on the “Bleeding Disorders Treatment Market” across the global, regional and country level. The report provides 360° analysis of “Bleeding Disorders Treatment Market” from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global PP Pipe industry, and estimates the future trend of Bleeding
Global Autoimmune Drugs Market 2018-2023 AbbVie, Johnson & Johnson, Biogen
Autoimmune Drugs Market Research 2018 A market study "Global Autoimmune Drugs Market" examines the performance of the Autoimmune Drugs market 2018. It encloses an in-depth Research of the Autoimmune Drugs market state and the competitive landscape globally. This report analyzes the potential of Autoimmune Drugs market in the present and the future prospects from various angles in detail. The Global Autoimmune Drugs Market 2018 report includes Autoimmune Drugs market Revenue, market Share,